Diagnostics News and Research

RSS

Partners, Luminex team up to discover novel biomarkers, develop clinical assays

Luminex Corporation announced today that it has teamed with Partners HealthCare toward the discovery of novel biomarkers and development of clinical assays.

From Luminex 16 Feb 2011

GE Healthcare to leverage SAS technology to help hospitals address preventable adverse medical events

SAS, the leader in business analytics software and services, and GE Healthcare have entered into a joint development and marketing agreement by which GE Healthcare will leverage SAS technology to analyze and deliver relevant, detailed patient safety information to help hospitals address preventable adverse medical events.

14 Feb 2011

First chromogenic culture medium to simultaneously detect Salmonella and Shigella

Hardy Diagnostics, an ISO certified biomedical firm, is pleased to announce the release of HardyCHROM™ SS, a highly selective chromogenic medium recommended for use as a primary screening medium for the isolation and differentiation of Salmonella and Shigella spp. from stool cultures. These two pathogens can be easily distinguished from non-pathogenic enteric bacteria based on colony color.

14 Feb 2011

FDA approves Hologic's 3-D digital mammography system to diagnose breast cancer

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced the Company received approval from the U.S. Food and Drug Administration for its Selenia Dimensions digital breast tomosynthesis system.

From Hologic, Inc. 14 Feb 2011

Guide star and time-reversal mirror in biomedical imaging

Astronomers have a neat trick they sometimes use to compensate for the turbulence of the atmosphere that blurs images made by ground-based telescopes. They create an artificial star called a guide star and use its twinkling to compensate for the atmospheric turbulence.

11 Feb 2011

SeraCare first quarter revenue decreases 7% to $10.5 million

SeraCare Life Sciences, Inc., a global life sciences company providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics, today reported operational and financial results for its first quarter of fiscal year 2011, ended December 31, 2010.

11 Feb 2011

Withings WiFi Body Scale that imports body weight data directly into Gazelle now available

Quest Diagnostics and Withings announced that the Withings WiFi Body Scale, the world's first WiFi connected personal weight scale, can now automatically import body weight data directly into Gazelle, the secure mobile health platform from Quest Diagnostics.

From Quest Diagnostics 11 Feb 2011

Patients with high blood pressure have benign endocrine tumours in adrenal gland: Research

High blood pressure may in some cases be caused by benign hormone-producing tumours of the adrenal cortex. A joint Swedish-American research effort has now uncovered a genetic cause behind the occurrence of such tumours. The findings were published today in the journal Science.

11 Feb 2011

HHS lists GE PSO as part of AHRQ Patient Safety Organization program

The Secretary of Health and Human Services has listed the GE-MERS National Patient Safety Organization as part of the Agency for Healthcare Research and Quality's Patient Safety Organization program. With this federal certification, GE Healthcare Performance Solutions joins leading healthcare organizations across the U.S. working to minimize risks in patient care.

11 Feb 2011

Presence of jumping genes, amplified oncogenes may be key to tumor progression: Researchers

The Massachusetts General Hospital research team that first discovered tumor-associated RNA in tiny membrane-enclosed sacs released into the bloodstream by cancer cells has now found that these microvesicles also contain segments of tumor DNA, including retrotransposons - also called "jumping genes" - that copy and insert themselves into other areas of the genome.

10 Feb 2011

GE Healthcare, BHS announce planned implementation of HIE

GE Healthcare and Butler Health System, which serves Western Pennsylvania communities, have announced the planned implementation of a health information exchange to enable clinical information access between BHS and its affiliated and independent physicians, as well as referral hospitals outside of the immediate community.

10 Feb 2011

Full genetic blueprint of multiple prostate tumors laid bare

For the first time, researchers have laid bare the full genetic blueprint of multiple prostate tumors, uncovering alterations that have never before been detected and offering a deep view of the genetic missteps that underlie the disease. The study, made possible by key advances in whole genome sequencing and analysis, points to several new prostate cancer genes and a critical category of genomic changes as important drivers of prostate cancer growth.

10 Feb 2011

FDLI's new Policy Forum takes close look on emerging health care liability issues

The ability of families to sue vaccine producers for faulty design could lead to a rise in litigation and force manufacturers to abandon the market, which, in turn, could cause disastrous public health consequences in the United States, assert Daniel J. Gage, Assistant Director and Alison R. Perencevich, Legislative Assistant, at the American Academy of Pediatrics' Department of Federal Affairs.

10 Feb 2011

Key advance in development of fast, simple test for detection of cholera

With cholera on the rampage in Haiti and almost 40 other countries, scientists are reporting the development of a key advance that could provide a fast, simple test to detect the toxin that causes the disease. The report appears in ACS' journal Bioconjugate Chemistry. Cholera affects more than 200,000 people annually, mainly in developing countries, and causes about 5,000 deaths. Many involve infants, children, and the elderly.

10 Feb 2011

CHI commends FDA's recognition of more efficient regulatory pathway for innovative medical devices

"CHI commends the FDA for its recognition of the need for a more efficient regulatory pathway for innovative medical devices that have the potential to improve lives," said CHI President and CEO David L. Gollaher, Ph.D. "It is essential that the FDA maintains focus on initiatives that strengthen the medical device review process, bringing greater clarity and consistency, while ensuring the U.S. maintains its competitive edge."

10 Feb 2011

Akonni signs license agreement with USAMRIID to develop multiplex testing products for bio-security applications

Akonni Biosystems, a molecular diagnostics (MDx) company that develops rapid, low-cost and highly scalable solutions for infectious disease testing, today announced it has signed a license agreement with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).

10 Feb 2011

WIN Consortium proposes unique alliance to fight cancer

WIN Consortium proposes a unique alliance to fight cancer and invites you to join the 3rd annual symposium: Gateways to efficacy of cancer diagnostics and therapeutics to be held on 6th to 8th of July at the Palais des Congrès in Paris, France.

10 Feb 2011

BD and UCLB enter agreement for development of new diagnostics for ovarian, breast cancer

UCL Business (UCLB), a wholly owned subsidiary of University College London (UCL), and BD (Becton, Dickinson and Company), a leading global medical technology company, announced today an agreement aimed at improving the early detection of ovarian and breast cancers to ultimately enable earlier and more effective treatment.

From BD (Becton, Dickinson and Company) 10 Feb 2011

BG Medicine underwriters exercise over-allotment option in full

BG Medicine today announced that the underwriters of its initial public offering have exercised in full their over-allotment option to purchase an additional 750,000 shares of BG Medicine's common stock at $7.00 per share, less underwriting discounts and commissions.

10 Feb 2011

Myriad Genetics' 46-gene PROLARIS molecular diagnostic test predicts prostate cancer outcome

Myriad Genetics, Inc. announced today that a study published in Lancet Oncology shows the Company's 46-gene PROLARIS™ molecular diagnostic test significantly predicts prostate cancer outcome.

10 Feb 2011

Diagnostics News and Research

Partners, Luminex team up to discover novel biomarkers, develop clinical assays

GE Healthcare to leverage SAS technology to help hospitals address preventable adverse medical events

First chromogenic culture medium to simultaneously detect Salmonella and Shigella

FDA approves Hologic's 3-D digital mammography system to diagnose breast cancer

Guide star and time-reversal mirror in biomedical imaging

SeraCare first quarter revenue decreases 7% to $10.5 million

Withings WiFi Body Scale that imports body weight data directly into Gazelle now available

Patients with high blood pressure have benign endocrine tumours in adrenal gland: Research

HHS lists GE PSO as part of AHRQ Patient Safety Organization program

Presence of jumping genes, amplified oncogenes may be key to tumor progression: Researchers

GE Healthcare, BHS announce planned implementation of HIE

Full genetic blueprint of multiple prostate tumors laid bare

FDLI's new Policy Forum takes close look on emerging health care liability issues

Key advance in development of fast, simple test for detection of cholera

CHI commends FDA's recognition of more efficient regulatory pathway for innovative medical devices

Akonni signs license agreement with USAMRIID to develop multiplex testing products for bio-security applications

WIN Consortium proposes unique alliance to fight cancer

BD and UCLB enter agreement for development of new diagnostics for ovarian, breast cancer

BG Medicine underwriters exercise over-allotment option in full

Myriad Genetics' 46-gene PROLARIS molecular diagnostic test predicts prostate cancer outcome

Event guide: 16th Clinical Biomarkers & CDx Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News